Ryvu Therapeutics (formerly Selvita) is now trading as a standalone biotech after its drug discovery services business was spun out in October 2019. According to the recent Q319 report, R&D progress is on track and 2020 is shaping up to be rather eventful, including expected data readouts from the two clinical trials with lead assets SEL120 and SEL24/MEN1703. Although the trials are early in terms of clinical development (Phase Ib and Phase I/II), they both include secondary endpoints, wh
04 Dec 2019
Ryvu Therapeutics - First ever clinical data from lead assets in 2020
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Ryvu Therapeutics - First ever clinical data from lead assets in 2020
- Published:
04 Dec 2019 -
Author:
Dr Jonas Peciulis -
Pages:
7
Ryvu Therapeutics (formerly Selvita) is now trading as a standalone biotech after its drug discovery services business was spun out in October 2019. According to the recent Q319 report, R&D progress is on track and 2020 is shaping up to be rather eventful, including expected data readouts from the two clinical trials with lead assets SEL120 and SEL24/MEN1703. Although the trials are early in terms of clinical development (Phase Ib and Phase I/II), they both include secondary endpoints, wh